Imatinib Drugs Market To Reach $2.52 Billion by 2035

Imatinib drugs market was valued at $1.80 billion in 2025 and is projected to reach $2.52 billion by 2035, growing at a CAGR of 4.3% during the forecast period (2026–2035). The market growth is primarily driven by the rising global burden of cancer, particularly hematological malignancies. According to the World Health Organization, cancer accounted for nearly 10 million deaths worldwide in 2022, with leukemia representing a significant share of cases. Imatinib remains a first-line targeted therapy for Chronic Myeloid Leukemia (CML) and other rare cancers, supporting sustained demand. Increasing access to generic imatinib formulations, especially in emerging economies, is further expanding patient reach and improving affordability, thereby strengthening market growth.

Browse the full report description of “Imatinib Drugs Market Size, Share & Trends Analysis Report, By Product Type (Branded Imatinib, Generic Imatinib), By Dosage Form (Tablets, Capsules), By Application (Chronic Myeloid Leukemia (CML), Gastrointestinal Stromal Tumors (GIST), Acute Lymphoblastic Leukemia (Ph+ ALL), Dermatofibrosarcoma Protuberans (DFSP), Other Rare Indications), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/imatinib-drug-market-share

Rising Prevalence of Leukemia and Targeted Therapy Adoption
Globally, the increasing incidence of leukemia is reinforcing the demand for tyrosine kinase inhibitors such as imatinib. Data from World Health Organization indicates that leukemia accounts for over 474,000 new cases annually. The shift toward targeted therapies over conventional chemotherapy is accelerating treatment adoption due to improved survival outcomes and reduced side effects. Governments and healthcare organizations are increasingly promoting early diagnosis and access to oncology drugs, further supporting imatinib utilization across both developed and developing regions.

Pharmaceutical Expansion and Oncology Drug Accessibility
The expansion of oncology drug manufacturing and generic drug penetration is a major factor contributing to market growth. According to the European Federation of Pharmaceutical Industries and Associations, Europe alone accounts for a significant share of global pharmaceutical production, supporting the supply of oncology medicines. In parallel, regulatory approvals for generics across regions such as Asia-Pacific and Latin America are increasing treatment accessibility. The growing role of public healthcare systems and reimbursement policies is also encouraging the adoption of cost-effective generic imatinib drugs.

Innovation and strategic initiatives shaping market competition
Leading pharmaceutical companies are actively focusing on product expansion, geographic penetration, and portfolio diversification to strengthen their market presence. Key players such as Novartis AG, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Viatris Inc., and Dr. Reddy’s Laboratories Ltd. are investing in expanding their oncology portfolios and strengthening global distribution networks.

• In April 2026, Cogent Biosciences completed a New Drug Application (NDA) submission to the FDA under the Real-Time Oncology Review program for bezuclastinib. This therapy targets patients with Gastrointestinal Stromal Tumors (GIST) who have previously developed a resistance to or failed prior treatment on Imatinib (Novartis's Gleevec).
• In January 2026, Viatris expanded its innovative cardiovascular portfolio with the first commercial launch of Inpefa® (sotagliflozin). The drug is indicated for the treatment of heart failure, pushing Viatris further into high-barrier branded therapy segments.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
• Product Type
• Dosage Form
• Application
• Regions Covered-
• North America
• Europe
• Asia-Pacific
• Rest of the World
• Competitive Landscape- Novartis AG, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Viatris Inc., Dr. Reddy’s Laboratories Ltd., among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Imatinib Drugs Market Report Segment

By Product Type

• Branded Imatinib
• Generic Imatinib

By Dosage Form

• Tablets
• Capsules

By Application

• Chronic Myeloid Leukemia (CML)
• Gastrointestinal Stromal Tumors (GIST)
• Acute Lymphoblastic Leukemia (Ph+ ALL)
• Dermatofibrosarcoma Protuberans (DFSP)
• Other Rare Indications (grouped to avoid overlap)

Global Imatinib Drugs Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/imatinib-drug-market-share